Cipla Readies gSymbicort, Semaglutide Amid Sale Speculation ‘Distraction’

"Very small investment” in gene editing/sequencing on cards

Cipla’s US business scales new peak in Q2 amid strong showing overall even as the promoter group stake sale speculation is becoming a 'distraction'. The company has new peptide assets, among others, in the wings while management also points to traction in the 'mRNA journey'.

New revenue peaks at Cipla • Source: Shutterstock

Cipla Limited delivered a strong set of numbers in the second quarter of fiscal 2024 and also outlined pipeline promise, though uncertainty and ongoing speculation around a potential stake sale by the promoter group may be fueling some “distraction” across the ranks. (see side box)

Stake Sale Speculation

Cipla’s senior management gave little away when it came to speculation around the founding Hamied family’s talks for a potential stake sale.(Also see "'Evergreen' Cipla: Chair Hamied Talks New Technologies Amid 'Speculative' Sale News" - Scrip, 11 August, 2023.)

Cipla’s MD and global CEO, Umang Vohra sought to distinguish between the promoters and the company. "We have not heard anything, either way, in terms of the transactions yet. We've been saying that this is speculative from the beginning. We maintain that if there is ever anything that requires a public disclosure, it will be disclosed at that time,” Vohra reiterated at a media briefing.(Also see "Will More Indian Family-Owned Firms Hand Over The Baton To PEs?" - Scrip, 31 July, 2023.)

The executive, though, did indicate that the on-and-off speculation and related uncertainty was leading to some anxiety, though Cipla’s philosophy has always been about investing for the future and “events” should not make a difference to that.

“As a human being, I'm anxious because so many things depend on this decision. Obviously, all of us continuing to work in the organization, that's one big thing,” Vohra said.

“What's more important is just the distraction that this could cause in the business. We're all human beings and get distracted with what happens and that distraction creates difficulties for us in the way we engage with each other and we engage with the organization. That I believe is the biggest impact of this uncertainty”.

Private equity firms and peer Torrent Pharmaceuticals Ltd. have been speculated to be in the fray to acquire a holding in Cipla, though reports in the local media suggest that valuation differences have cropped up stalling, at least for now, Torrent’s most ambitious M&A manoeuvre so far in its long history.(Also see "India M&A Hourglass: Control Deals, ‘FOMO’, Monetization Calls At Family-Owned Firms" - Scrip, 12 September, 2023.)(Also see "Torrent Evasive On Cipla Question, But Comfortable With Domestic Acquisitions" - Scrip, 27 October, 2023.)(Also see "More Interest In Speculated Cipla Stake Sale: Portfolio, Cultural Fit Will Matter" - Scrip, 4 September, 2023.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By 

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.

More from Scrip

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.